CARsgen Therapeutics Company
%20.jpg)
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Headquarters:
China
Last Funding Type:
Series C
Last Funding Date:
44137
Employee Number:
11-50
Founded Date:
11-1
Technology:
diagnostics
Estimated Revenue:
$1M to $10M
Industry:
Health Diagnostics, Medical, Therapeutics
Funding Status:
Late Stage Venture